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Summary
Periprosthetic infections are life-threatening compli-
cations that occur in about 6% of medical device in-
sertions. Stringent sterile techniques have reduced
the incidence of infections, but many implant patients
are at high risk for infection, especially the elderly,
diabetic, and immune compromised. Moreover, be-
cause of low vascularity at the site of the new implant,
antibiotic prophylaxis is often not effective. To ad-
dress this problem, we designed a covalent modifica-
tion to titanium implant surfaces to render them bac-
tericidal. Specifically, we aminopropylated titanium, a
widely used implant material and extended a tether
by solid phase coupling of ethylene glycol linkers, fol-
lowed by solid phase coupling of vancomycin. Vanco-
mycin covalently attached to titanium still bound sol-
uble bacterial peptidoglycan, reduced Staphylococcus
aureus colony-forming units by 88% ± 16% over 2 hr,
and retained antibacterial activity upon a repeated
challenge.
Introduction
Implant-associated infections are serious complica-
tions of medical device insertions [1–3]. An estimated
11 million people in the United States alone have re-
ceived at least one implanted medical device [4]. Suf-
fering and additional health costs due to implant infec-
tions are a major public health problem. Such infections
are difficult to treat for two principal reasons. The first
of these is that the implant is surrounded by a fibrous
coating, as is typical in the response to a foreign body.
This encapsulation provides a protected environment
for bacterial growth that is largely inaccessible to the
host immune system. The second reason is that bacte-
ria such as Staphylococcus aureus (S. aureus) adhere
readily to implant surfaces. Thus the implant surface,
which is coated with a host of extracellular matrix se-
rum proteins, provides an ideal environment to facilitate
bacterial adhesion and proliferation to ultimately result
in a bacterial population encased in a polysaccharide
glycocalyx, termed a biofilm. At this point, the biofilm-
coated surface is largely resistant to pharmacological
agents as well as host defenses [5, 6]. Implant-associ-
ated infections can arise in the weeks immediately fol-*Correspondence: eric@tesla.jci.tju.edu
4 Present address: SK Biopharmaceuticals, Fairfield, NJ 07004.
5 Lab address: http://tesla.jci.tju.edulowing surgery due to contamination; at later times, in-
fections can arise from hematogenous sources, such
as urinary tract infections and periodontal disease. In
joint replacements, treatment entails aggressive sys-
temic and local antibiotic treatment, debridement, and,
in many cases, implant removal and reimplantation. De-
spite aggressive antibiotic treatment, eradication of
established implant-associated infections often fails [3,
7–9]. Difficult cases lead to arthrodesis, amputation,
or death.
Current clinical practice relies on insertion of antibi-
otic-impregnated bone cement, usually in the form of
spacer blocks [10]. Such blocks suffer from poor elu-
tion profiles, material properties, and the requirement
for surgical removal. Controlled-release, antibiotic-impreg-
nated biodegradable materials have been developed for
this application [11–16]. However, they suffer from fra-
gility and/or undesirable modification of the implant en-
vironment during their degradation. Importantly, these
materials deliver active prophylaxis only from the time
of implantation and last at most only through the imme-
diate postoperative period [17]. Thus, delivery of local
antibiotic prophylaxis is less than ideal with the materi-
als described above. A new paradigm to interdict deep-
seated bone infections both in the immediate postop-
erative period and throughout the life of the implant
would have great clinical importance for implant surgery.
We hypothesized that permanent covalent bonding
of drugs to implants would provide the desired protec-
tion. For the first test of the permanent covalently
bonded strategy, we examined titanium (Ti), a metal
with excellent biocompatibility that is commonly used
either in its pure state or as an alloy in the fabrication
of orthopaedic and dental implants. Ti biocompatibility
appears to depend not on its bulk properties but on the
Ti-OH surface layer, which displays a dielectric con-
stant of 80 or more [18], very close to that of water.
Importantly, Ti and its alloys osseointegrate, that is,
bone and its matrix come into stable association with
the metal implant, thus allowing stable fixation of the
implant.
Osseointegration of Ti implants has been enhanced
through altering surface topography, as well as through
surface adsorption or surface modification with bioac-
tive molecules to enhance osseointegration [19–21], for
example, fabrication of an interconnected porous Ti
surface, or adsorption of calcium phosphate [22]. The
Ti-OH surface layer is sufficiently reactive to allow si-
lanization [23]. Because the 3d2 outer shell orbitals of
titanium are similar in reactivity to the 3p2 orbitals of
silicon, the Ti-OH outer layer of Ti metal can be amino-
propylated just like Si-OH to permit permanent attach-
ment of interesting molecules. This approach has been
used to attach bioactive peptides, enzymes, and pro-
teins to glass, titanium, quartz, and silicone aminopro-
pylated surfaces [23–30].
Although antibiotics have not yet been covalently
bonded to Ti implant devices, coupling to Ti through
aminopropylation seemed conducive to antibiotic at-
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products would be bacteriostatic or bactericidal, creat-
ing a stable microenvironment with a similar spectrum
as the soluble antibiotics. Such self-protecting implants
represent the beginning of a new generation of pros-
thetic devices that could lower the incidence of im-
plant-associated infections, prevent bacterial biofilm
formation, and ultimately decrease revision surgeries
due to infection-associated implant loosening. In this
model, antibiotic protection of implant surfaces would
not be compromised by bone implant cement because
bacterial colonization of the metal surface beneath the
cement constitutes the central problem.
We chose the well-studied antibiotic vancomycin
(VAN) (Figure 1) to bond to Ti because VAN provides
potent treatment for a large spectrum of Gram-positive
bacterial infections, the most common causes of noso-
comial and hematogenous periprosthetic infections
[31–33]. VAN blocks steps in the biosynthesis of the
peptidoglycan layer of the cell wall of Gram-positive
bacteria by binding to L-Lys-D-Ala-D-Ala termini of the
nascent peptidoglycan (Figure 1) [34, 35], thereby pre-
venting the crosslinking that is necessary for osmotic
stability. In fact, membrane-localized VAN shows en-
hanced activity against VAN-resistant S. aureus [36]. As
the C-terminal carboxylic acid of VAN is not necessary
for antibiotic activity [37–39], it is suitable for covalent
coupling of VAN to the aminopropylated Ti surface.
Thus, it is reasonable to hypothesize that VAN could be
tethered to Ti beads via linkers and could kill suscepti-
ble bacteria by acting at the inner leaflet of the bacterial
cell wall. Here we report the synthesis, characterization,
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mFigure 1. Mechanism and Structure of VAN
Bonded to Ti
(A) Inhibition of transpeptidation and trans-
glycosylation steps of cell wall biosynthesis
by VAN through the binding of the D-Ala-
D-Ala termini of peptidoglycan with VAN by
five hydrogen bonds.
(B) Schematic of the proposed VAN-tethered
Ti implant material.igand binding activity, and infection control of S. aureus
ith VAN-tethered Ti beads.
esults and Discussion
esign of Antibiotic-Tethered Metal Implant
mplant-associated infection can be recalcitrant to
reatment, suggesting that prevention is the best strat-
gy. One way to prevent the establishment of infection
s to render the implant surface bactericidal via cova-
ent modification. Specifically, we planned to produce
bactericidal surface by coupling VAN to a Ti surface
erivatized with 3-aminopropyltriethoxysilane (APTS;
H2PrSi(OEt)3) (Figure 2). We were particularly inter-
sted in using Ti as the metal in our initial studies be-
ause of its demonstrated superiority over other ortho-
aedic implant materials.
Therefore, we hypothesized that an antibiotic could
e bonded to aminopropylated Ti (NH2PrSiOTi) by solid
hase peptide synthesis (Figure 2). We tested this hy-
othesis by measuring two key properties: (1) binding
f Ti-coupled VAN to its macromolecular target; and (2)
actericidal or bacteriostatic action of Ti-coupled VAN
gainst adherent bacteria.
To extend VAN away from the silanized Ti surface, we
hose 8-amino-3,6-dioxaoctanoate (aminoethoxyethoxy-
cetate; AEEA), a flexible linker that is hydrophilic due
o the presence of ether linkages in the molecule and
mide linkages to the Ti particles and to VAN. We hy-
othesized that extending VAN away from the Ti sur-
ace by the length of two AEEA linkers and the NH2PrSi
odification (24 bonds, z40 Å) would be sufficient to
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1043Figure 2. Reaction Scheme for Synthesis of
VAN Bonded to Ti
(a) Toluene, room temperature. (b) (i) Fmoc-
AEEA, HATU, Me2NCHO, N-methylmorpholine,
room temperature; (ii) Piperidine/Me2NCHO;
(iii) Fmoc-AEEA, HATU, Me2NCHO, N-methyl-
morpholine, room temperature; (iv) Piperi-
dine/Me2NCHO. (c) VAN, HATU, Me2NCHO,
N-methylmorpholine, room temperature.allow VAN to enter the bacterial cell wall to bind to
L-Lys-D-Ala-D-Ala termini of the peptidoglycan precur-
sors. A schematic of the proposed implant material is
shown in Figure 1, illustrating the interaction of VAN
with the L-Lys-D-Ala-D-Ala terminus of the peptidogly-
can precursors.
Synthesis and Characterization
of VAN-Tethered Ti Implant
We tethered VAN to the Ti-OH surface via NH2PrSi
(OEt)3 and AEEA linkers (Figure 2). We derivatized Ti
particles (1) with 5% (v/v) NH2PrSi(OEt)3 (2) in toluene
under argon to generate NH2PrSiOTi beads (3; a struc-
ture reflecting low NH2PrSi modification). Ninhydrin as-
says of NH2PrSiOTi particles gave yields of 8–12 mol
of amine per gram of beads. Two Fmoc-AEEA linker
groups (4) and VAN were then coupled sequentially to
the NH2PrSiOTi beads (3) by solid phase peptide syn-
thesis using N-[(dimethylamino)-1-H-1,2,3-triazolo[4,5-
b]pyridin-1-ylmethylene]-N-methylmethanaminium
hexafluorophosphate N-oxide (O-(7-azabenzo-triazole-
1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate;
HATU) as the coupling reagent. The Fmoc groups were
cleaved with 20% piperidine in anhydrous Me2NCHO;
quantitation of the absorbance spectra of the Fmoc de-
protection solutions showed stoichiometric addition of
each of the two AEEA linkers to the NH2PrSiOTi sup-
port. Linker coupling was also quantitated by ninhydrin
assays of amine functional groups on the Ti beads fol-
lowing Fmoc deprotection.
Covalent coupling of VAN to the AEEA linkers and
attachment to the NH2PrSiOTi particles was tested by
cleavage of Si-O-Ti bonds with Bu4NF, a mild deprotec-
tion reagent for silyl protection groups [40]. The cleaved
product was analyzed by MALDI-TOF mass spectros-
copy (Figure 3). A peak corresponding to the cleaved
VAN-AEEA-AEEA-NHPrSiF3 was observed at 1863 Da.
Other cleavage products were observed at 1616 Da
(VAN-AEEA-COOH + Na), 1576 Da (VAN-AEEA-OH),
1549 Da (VAN-AEEA-COO−), and 1514 Da (VAN-CO-NH-
CH2-CH2-OH + Na). Based on the assignments of these
fragments, we concluded that the Ti beads were deri-medium (DMEM) containing 10% fetal bovine serum for
Figure 3. MALDI-TOF Mass Spectrum of Cleaved VAN-AEEA-
AEEA-NHPrSiOH
Ti-O-Si bonds were cleaved with 1 M Bu4NF in tetrahydrofuran for
2 hr at room temperature.vatized by NH2PrSi(OEt)3, coupled to two AEEA linker
groups, and covalently bound to VAN.
Analysis of VAN Distribution on the Ti Surface
To further analyze the presence and distribution of VAN
bonded to the Ti surface, VAN coverage was visualized
with a specific anti-VAN antibody using indirect immu-
nofluorescence (Figure 4D). Thus, VAN derivatization
was apparent by immunofluorescence and appeared to
cover the surface evenly, with areas of focal concentra-
tions. When control Ti particles were stained, little fluo-
rescence was observed (Figure 4A). The control Ti
beads coveredw50% of the well (Figure 4B). When the
VAN-AEEA-AEEA-NHPrSiOTi particles were stained,
diffuse fluorescence was present (Figure 4C) that cor-
responded to the distribution of Ti beads (Figure 4D).
Thus, VAN derivatization was apparent by immunofluo-
rescence and appeared to cover the surface evenly,
with areas of focal concentrations. To begin to address
the question of long-term stability, the VAN distribution
was also examined in a different batch of particles that
had been incubated in Dulbecco’s modified essential
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1044Figure 4. Immunofluorescent Detection of VAN on Ti Particles
Ti or VAN-AEEA-AEEA-NHPrSiOTi beads were incubated with anti-
VAN antibody for 24 hr, followed by incubation with an AlexaFluor
488-coupled secondary antibody. Left: fluorescence; right: bright
field. Results are shown for newly synthesized particles (A–D) and
for particles that had been incubated with DMEM containing 10%
fetal bovine serum, 25°C for 3 weeks (E–H). Specific binding of the
anti-VAN antibody was detected by confocal laser scanning micro-
scopy (new: [A] and [C]; 3 weeks: [E] and [G]) and particle distribu-
tion was determined by a bright field image (new: [B] and [D]; 3
weeks: [F] and [H]). Control Ti beads (new: [A]; 3 weeks: [E])
showed little specific signal associated with binding of the anti-
VAN antibody, whereas VAN-AEEA-AEEA-NHPrSiOTi particles showed
diffuse staining (new: [C]; 3 weeks: [G]) that corresponded to the
distribution of the beads in the well (new: [D]; 3 weeks: [H]). The
scale bar represents 50 m.
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L3 weeks at room temperature (Figures 4E–4H). As in the
newly synthesized particles, binding of the VAN anti-
body to the control Ti beads after incubation was mini-
mal (Figure 4E), whereas significant binding was ob-
t
m
b
derved with the VAN-AEEA-AEEA-NHPrSiOTi particles
Figure 4G) assessed under the same conditions. Taken
ogether, these images imply stability of VAN on the Ti
urface for at least 3 weeks.
nalysis of Biochemical Activity of VAN
y Ligand Binding
he biochemical activity of covalently bound VAN was
ested with a substrate binding assay. Washed Ti,
H2PrSiOTi, and VAN-AEEA-AEEA-NHPrSiOTi were in-
ubated in physiological buffer (0.15 M NaCl, 0.01 M
a2HPO4 [pH 7.4]; PBS) in the presence of soluble
eptidoglycans containing multiple L-Lys-D-[14C]Ala-D-
14C]Ala termini [41, 42]. Specific peptidoglycan binding
as determined by liquid scintillation counting of un-
ound radioactivity. VAN-AEEA-AEEA-NHPrSiOTi par-
icles bound 50%–60% of the labeled peptidoglycan,
hile NH2PrSiOTi or unmodified Ti beads bound only
15% of the labeled peptidoglycan. To reduce non-
pecific binding, particles were also incubated with
.1% (w/v) bovine serum albumin in 0.15 M NaCl, 0.01
(HOCH2)3CNH2-HCl (pH 7.4), 0.1% Tween-20 (TBST)
rior to addition of labeled soluble peptidoglycan.
-Lys-D-[14C]Ala-D-[14C]Ala soluble peptidoglycan bind-
ng was reduced overall, with VAN-AEEA-AEEA-NHPr
iOTi particles binding w25% of the label compared
ith 5% or lower for NH2PrSiOTi or unmodified Ti
eads. These data imply that VAN tethered to Ti beads
an still bind its peptidoglycan ligand specifically.
ntibacterial Activity Assay
n VAN-Tethered Ti Particles
taphylococci account for the majority of orthopaedic
mplant device-related infections; S. aureus is the most
ommon pathogen identified [2, 8, 43, 44]. The ability
f S. aureus to adhere to the extracellular matrix and
lasma proteins deposited on biomaterials is a signifi-
ant factor in the pathogenesis of medical device-
elated infections [45, 46]. For these reasons, we chose
. aureus to study the antibacterial activity of the VAN-
EEA-AEEA-NHPrSiOTi beads.
The antibacterial activity of VAN-AEEA-AEEA-NHPrSi
Ti particles was determined by static incubation with
1 × 104 cfu active S. aureus at 37°C with Ti or VAN-
EEA-AEEA-NHPrSiOTi particles for 2 hr. S. aureus
ncubation with VAN-AEEA-AEEA-NHPrSiOTi showed
ignificant antibacterial effects at each time point com-
ared to the incubation with Ti particles (Figure 5). In
act, VAN-AEEA-AEEA-NHPrSiOTi surfaces reduced
he colony formation by 76% ± 15% at 1 hr and 88% ±
6% at 2 hr when compared to controls. Thus, based
n bacterial proliferation assays, the VAN-AEEA-AEEA-
HPrSiOTi beads markedly reduced colony counts,
uggesting a potent bactericidal effect.
Based on these results, we examined the appear-
nce of the particles after incubation withz1 × 104 cfu
ctive S. aureus for 1 hr at 37°C. Control Ti or VAN-
EEA-AEEA-NHPrSiOTi samples were stained with
ive/Dead BacLight kit (Molecular Probes, Eugene, OR)
hat differentiates viability based on differential dye per-
eability (Figure 6). When S. aureus cells were incu-
ated with Ti beads, most cells remained alive, as evi-
enced by predominantly green staining (Figure 6A
Vancomycin-Titanium Beads
1045Figure 5. Ti-Tethered VAN Inhibits Proliferation of S. aureus
Control Ti (solid bars) or VAN-AEEA-AEEA-NHPrSiOTi (Ti-VAN,
open bars) particles were incubated with S. aureus under static
conditions for up to 120 min. Colony counts were determined by
direct counting after serial dilution plating. Incubation of S. aureus
with VAN-AEEA-AEEA-NHPrSiOTi resulted in significantly de-
creased colony counts at all times sampled. S. aureus in control
cultures maintained colony counts without robust proliferation as
would be expected in static cultures. Normalized data are shown
as a percentage of Ti control at 30 min. The asterisks imply statisti-
cal significance in reference to the corresponding time control at
p < 0.05.VAN-resistant mutant bacteria. An environment that is
Figure 6. Ti-Tethered VAN Kills Adherent
S. aureus
Ti (A–C) or VAN-AEEA-AEEA-NHPrSiOTi
(D–F) particles were incubated with S. aureus
for 1 hr. In the control Ti sample, green stain-
ing of live cells (A) was more intense than
the parallel red signal for dead cells (B). In
contrast, the VAN-AEEA-AEEA-NHPrSiOTi
beads displayed only scattered green stain-
ing for live cells (D) with the greatest red
staining for dead cells (E). (C) and (F) show
the corresponding bright field images of the
particle distribution in each assay. The scale
bar represents 100 m.
mide), yielding a measured KD of (4 ± 1) × 10 M [49].versus 6B; bright field image of the particles is shown in
Figure 6C). In contrast, S. aureus incubated with VAN-
AEEA-AEEA-NHPrSiOTi beads were predominantly dead,
as indicated by red staining (Figure 6D versus 6E; bright
field in Figure 6F). When beads that had been exposed
the day before to S. aureus were washed, rechallenged,
and stained, VAN-AEEA-AEEA-NHPrSiOTi retained its
ability to kill S. aureus preferentially (not shown). These
staining and proliferation assay results imply that the
VAN-AEEA-AEEA-NHPrSiOTi surface actively killed
S. aureus.
Antibiotic Resistance
Before introducing a new and stable form of VAN in
vivo, one must consider the possibility of selection forpermissive for the selection of resistant organisms re-
lies on (1) the presence of millions of bacteria, charac-
teristically encountered in the gut and the oral cavity
and (2) prolonged exposure to concentrations of antibi-
otics sufficient to suppress growth of sensitive organ-
isms but insufficient to suppress insensitive organisms
[47]. In the first case, the number of bacteria that initiate
periprosthetic infections is small and as the antibiotic
is constrained on the Ti surface, the number of bacteria
exposed to the antibiotic is smaller still. Under these
circumstances, the probability of a mutation that con-
fers a selective growth advantage to a low number of
bacteria is vanishingly small. With respect to the sec-
ond possibility, the dissociation constant of VAN from
L-Lys-D-Ala-D-Ala in solution is 1 × 10−6 M [48]; thus,
at limiting concentrations of soluble VAN monomers,
enough peptidoglycan precursors are unoccupied at
any moment for some bacteria to survive and grow
slowly, providing an ideal situation to select for a mu-
tant peptidoglycan with a terminal D-Ala-D-Lac that
binds weakly to VAN [11].
That situation is much less likely for a solid phase
material bearing multiple VAN residues. In suspension
culture, a single bacterium presents thousands of
L-Lys-D-Ala-D-Ala precursor peptidoglycan binding
sites for soluble VAN over the surface of its cell wall.
For a bacterium sitting on a bed of multiple solid phase
VAN moieties, bound by each of thousands of accessi-
ble peptidoglycans to thousands of VAN residues on
the Ti surface, dissociation of that bacterium would re-
quire simultaneous cooperative undocking of all pepti-
doglycans from all VAN-AEEA-AEEA-NHPrSiOTi sites at
the same instant. The dissociation constant for multiple
peptidoglycan-VAN complexes is the product of the
multiple dissociation constants. That is, the KD for two
peptidoglycans from two solid phase VAN moieties is
(10−6 × 10−6 M) = 10−12 M. For three peptidoglycans
simultaneously escaping from three VAN residues, one
calculates similarly KD = 10−18 M. This analysis was vali-
dated by a specific test of 1,3,5-tris(CONH(N-acetyl)-L-
Lys-D-Ala-D-Ala) benzene binding to tris(VAN carboxa-
−17
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rium binding to 100 VAN on a Ti surface, KD rises to
10−600 M, implying no detectable escape of any bound
bacterium until the dead fragments dissociate one by
one. In other words, simultaneous binding to thousands
of solid phase VAN moieties has an effect equivalent to
an enormous solution concentration of free VAN. This
phenomenon potentiates the bactericidal action of
VAN.
The most common VAN resistance mutation is a
change of peptidoglycan target from D-Ala-D-Ala to
D-Ala-D-Lac. The dissociation constant of VAN from the
mutant peptidoglycan will increase to 10−3 M [50]. In
that situation, we could extrapolate from the hypotheti-
cal example of 100 VAN binding to 100 mutant pepti-
doglycan precursor sites a KD of 10−300 M, but this re-
mains hypothetical in the absence of experiment. Thus,
both because the surface will be exposed to relatively
small numbers of microorganisms in vivo, and because
VAN will show an increased potency because of its sur-
face immobilization, occurrence of bacterial resistance
should be extremely unlikely.
Implications for Management of Implant Infections
The covalently tethered antibiotic approach is uniquely
suited to the eradication of a nascent infection and thus
could reduce the risk of implant-associated infections.
Bacterial infection in surrounding tissue and bone can-
not be controlled entirely by an antibiotic covalently
bonded to an implant surface, but might be managed
by a secondary route of release of soluble antibiotic on
demand. Moreover, this new paradigm could be easily
extended to other agents and materials. Applications of
such surfaces extend beyond orthopaedics. Indwelling
devices tend to serve as ideal surfaces for establish-
ment of infections. Thus, surface modifications that
render devices antibacterial for the long term offer
great promise for ameliorating the complications inher-
ent in implant-associated infections and their treat-
ment. Direct chemical modification of implant surfaces
with bactericidal agents could provide a new genera-
tion of implants that are able to combat implant-associ-
ated infection and its devastating consequences.
Significance
Bacterial adhesion to implanted biomaterial surfaces
is a critical step in the pathogenesis of infection. The
formation of a complex biofilm at the interface be-
tween a biomaterial and the biological environment is
thought to be responsible for sustaining and ex-
acerbating inflammation and for the ultimate failure
of biomedical devices. In this report, we have taken
the first steps toward the goal of producing a bacte-
ria-resistant implant. First, these studies demonstrate
for the first time, to our knowledge, that an antibiotic
can be covalently attached to a biocompatible implant
material. The synthesis was validated by step-by-step
analysis and by MALDI-TOF mass spectra of the final
product. Second, the solid phase antibiotic not only
retained the activity of the soluble antibiotic, but may
improve on the latter activity by preventing biofilm
formation at the site of the implant. Activity of the co-
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salently bound antibiotic was shown at the biochemi-
al level by specificity against the secreted peptido-
lycan target of the antibiotic. The tethered antibiotic
as also demonstrated to be active at the microbio-
ogical level by inhibition of bacterial proliferation and
iofilm formation. Finally, the covalently bound antibi-
tic maintained its stability as demonstrated by activ-
ty after a repeat challenge, and by its ability to bind
nti-VAN antibody after 3 weeks in culture medium
t room temperature. The titanium surface was thus
mpowered to protect itself from colonization by bac-
eria. These experiments demonstrate the potential of
ovalent implant modification for infection control.
nlike a noncovalent coating that slowly releases a
ree antibiotic, Ti-bonded VAN was not lost from the
urface during incubation with the bacteria. Thus, co-
alent binding can extend the microbiological activity
f VAN in precisely the microenvironment in which it
s most needed.
xperimental Procedures
hemicals
ll solvents were purchased from Fisher Scientific (Fair Lawn, NJ).
ll reagents for coupling reactions were purchased from Sigma-
ldrich (St. Louis, MO). Ti particles (350 mesh) were from Alfa Aesar
Ward Hill, MA).
erivatization of Ti Surfaces with NH2PrSi(OEt)3
i beads (5–10 g of 350 mesh) were cleaned with MeOH/concen-
rated HCl (1:1, 5 ml) for 20 min at room temperature with 20 sec
eriods of sonication at 0, 5, 12, 15, and 20 min. The cleaned par-
icles were washed twice with double-deionized water (5 ml), then
our times with anhydrous Me2NCHO (5 ml). Particles were dried
vernight under vacuum and placed in the argon atmosphere
hamber of an MO-20M glove box (Vacuum Atmospheres, Haw-
horne, CA). Particles were washed twice with anhydrous toluene
10 ml) by suspension with a stainless steel spatula, then reacted
ith 5% NH2PrSi(OEt)3 in anhydrous toluene (v/v, 5 ml) for 60 min
ith resuspension every 10 min. The beads were washed twice with
nhydrous toluene (10 ml) as above, washed twice with anhydrous
e2NCHO (10 ml) as above, and dried under vacuum overnight.
he beads were then baked at 100°C for 15 min in a convection
ven. Aliquots of z100 mg were assayed for amine content by
uspension in 0.35 mM SnCl2, 0.1 M Na citrate (pH 5; 1 ml), fol-
owed by the addition of 4% ninhydrin in EtOH (w/v, 1 ml). After
mmersion in boiling water for 15 min., the solution was cooled
or 2 min, diluted with EtOH/H2O (3:2, v/v, 5 ml), and amines were
uantitated by measuring the absorbance, A570, using 570 = 1.5 ×
04/M·cm.
olid Phase Coupling of VAN to the Ti Surface
H2PrSiOTi beads (1–2 g, 10–20 mol amine) were washed twice
ith anhydrous Me2NCHO (5 ml), then coupled with a 4-fold molar
xcess of Fmoc-8-amino-3,6-dioxaoctanoate (aminoethoxyethoxy-
cetate; AEEA) linker, activated with a 4-fold molar excess of HATU
n anhydrous Me2NCHO (5 ml), followed by Fmoc deprotection with
0% piperidine in anhydrous Me2NCHO (5 ml). The completeness
f deprotection was determined by Kaiser’s test. Similarly, a sec-
nd AEEA linker group was subsequently coupled to the beads. All
moc deprotection solutions and washes were collected for analy-
is. Finally, a 4-fold excess of VAN was coupled by the same proto-
ol. After the VAN coupling step, the Ti beads were washed twice
ith anhydrous Me2NCHO (5 ml), and then dried under vacuum
vernight. Absorbance spectra of the deprotection solutions were
ecorded and yields were calculated using A570 and 301 = 7.78 ×
03/M·cm.
leavage of Si-O Bond by Bu4NF Reaction and MALDI-TOF MS
atrix-assisted laser desorption ionization time of flight mass
pectrometry (MALDI-TOF) was used to characterize the molecular
Vancomycin-Titanium Beads
1047species covalently attached to the Ti surface. Specifically, the VAN-
AEEA-AEEA-NHPrSiOTi particles (z100 mg) were suspended in
Me2NCHO (0.5 ml), to which was added 1 M Bu4NF in tetrahydrofu-
ran (4 ml) with stirring for 2 hr at room temperature to cleave the
Si-O bonds. After filtering to remove Ti particles, the filtrate solution
was analyzed by MALDI-TOF mass spectrometry.
VAN Antibody Binding
Ti and VAN-AEEA-AEEA-NHPrSiOTi particles were washed twice
with PBS. The material was blocked for 30 min using 10% fetal
bovine serum in distilled, deionized water (dH2O, blocking buffer).
The beads were incubated with mouse anti-VAN IgG (1:300; U.S.
Biologicals, Swampscott, MA) in blocking buffer at 4°C for 12 hr,
washed with PBS, and incubated with AlexaFluor 488-coupled
donkey anti-mouse IgG (Molecular Probes, Eugene, OR) diluted
1:300 in blocking buffer at room temperature for 1 hr. Both Ti and
VAN-AEEA-AEEA-NHPrSiOTi particles were washed three times
with PBS, followed by two 15 min incubations in PBS. The particles
were then visualized using a Fluoview 300 confocal laser micro-
scope (Olympus, Melville, NY). For long-term experiments, the
beads were incubated in DMEM/10% fetal bovine serum for 3
weeks at room temperature, washed four times with PBS, followed
by incubation with blocking buffer for 15 min and staining as above.
Soluble Peptidoglycan Binding Assay for VAN
To determine the biological activity of VAN covalently bound to the
Ti particles, specific binding of VAN-AEEA-AEEA-NHPrSiOTi to the
VAN ligand L-Lys-D-Ala-D-Ala present on soluble peptidoglycan
was determined [41, 42]. Samples of Ti, NH2PrSiOTi, and VAN-
AEEA-AEEA-NHPrSiOTi beads (100 mg each) were washed by sus-
pension in PBS (1 ml) in a polypropylene vial, with rocking for 1 hr
at room temperature. The wash supernatant was removed, and the
particles were incubated with 2.5 nCi of L-Lys-D-[14C]Ala-D-[14C]Ala
soluble peptidoglycan, z10 Ci/mol, prepared as previously de-
scribed [41, 42] for 2 hr with rocking. Unbound soluble peptidogly-
cans in the supernatants were collected, and quantitated by liquid
scintillation counting in Aquasol II (PerkinElmer Life Sciences, Shel-
ton, CT; 10 ml) in an LS 6000SC scintillation spectrometer (Beck-
man Instruments, Fullerton, CA). To control for nonspecific binding,
the above beads were also analyzed using 0.1% (w/v) bovine se-
rum albumin in TBST in the washing step with samples rocked for
4 hr at room temperature, followed by incubation with 2.5 nCi of
L-Lys-D-[14C]Ala-D-[14C]Ala soluble peptidoglycan with rocking
overnight at 4°C and quantitation as above.
Bacterial Assays
The control Ti and VAN-AEEA-AEEA-NHPrSiOTi particles were ster-
ilized by incubation in 70% ethanol, followed by five PBS washes.
The beads were resuspended in 1% dextrose/PBS, and 30 l of
the suspension, corresponding to z40 mg of particles, were dis-
pensed into each well of an eight-well chamber slide (Nunc, Roch-
ester, NY). S. aureus subspecies aureus Rosenbach ATCC strain
25923 was cultured in trypticase soy broth for 12 hr. The culture
was pelleted by centrifugation at 3200 × g for 5 min, and resus-
pended in 1% dextrose/PBS. Using the McFarland standard, an
early log-phase aliquot of S. aureus containingz1 × 104 cfu in 170
l was inoculated in each well. The cultures were incubated at 37°C
for 30, 60, 90, and 120 min under static conditions.
Quantitative culture was performed at 30, 60, 90, and 120 min by
serially diluting 200 l of sample in 1.8 ml PBS, then plating 200 l
of the relevant dilutions in triplicate on Todd-Hewitt agar plates.
The number of cfu per ml was determined by counting the numbers
of colonies on plates after 24 hr, determining the mean per sample,
and adjusting for the dilution. Plates showing no growth after the
initial 24 hr incubation were kept for an additional 24 hr to confirm
the absence of growth.
For microscopy, the samples were washed twice with PBS to
remove planktonic bacteria. Viability of bacteria was determined at
1 hr by confocal laser microscopy (Olympus Fluoview 300) after
staining using the Live/Dead BacLight Viability kit (Molecular
Probes) that functions based on the differential membrane perme-
ability to Cyto9 and propidium iodide. After staining, upon excita-tion, live bacteria show an intense green fluorescence, while dead
bacteria fluoresce red.
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